CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

← catalyst calendar

NCT03328078 · readout ≤ 12 d

Sponsored by Curis, Inc. (industry) · CRIS — their whole pipeline →.

Phase

Phase 1/2

Status

Recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

152estimated

Sites

Countries

Czechia, France, Israel +4

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2017-12-28

actual

When the study began enrolling

Primary completion

Aug 2026

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Oct 2026

estimated

The whole study's end, after follow-up

First posted

2017-11-01

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-04-16

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Relapsed Hematologic Malignancy
Refractory Hematologic Malignancy
Relapsed Primary Central Nervous System Lymphoma
Refractory Primary Central Nervous System Lymphoma

Interventions

Drug: Emavusertib — also filed as CA-4948
Drug: Ibrutinib

Primary outcomes

what the primary-completion date above is the date OF

Part A: To determine the safety and tolerability of emavusertib as a monotherapy and in combination with ibrutinib: dose-limiting toxicity (DLT)

measured 12 months

Part A: Maximum tolerated dose (MTD) of emavusertib as a monotherapy and in combination with ibrutinib measured by dose-limiting toxicities (DLTs)

measured 12 months

Part A: Recommended Phase 2 Dose (RP2D) of emavusertib as a monotherapy and in combination with ibrutinib based on overall tolerability data

measured 12 months

Part B: Overall Response Rate (ORR) in participants with R/R PCNSL

measured 18 months

Part C: ORR in participants with R/R PCNSL

measured 18 months

Permalink · CRIS's whole pipeline · Catalyst calendar · Every registered study · What changed